jiali song

Ms. jiali song


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
JSjiali song
jiali song
ZXZhenyi Xu
Zhenyi Xu
LCLei Cao
Lei Cao
MWMeng Wang
Meng Wang
YHYan Hou
Yan Hou
KLKang Li
Kang Li
Drug–target interaction (DTIs) prediction plays a vital role in probing new targets for breast cancer research. Considering the multifaceted challenges associated with experimental methods identifying DTIs, the in silico prediction of such interactions merits exploration. In this study, we develop a feature-based method to infer unknown DTIs, called PsePDC-DTIs, which fuses information regarding protein sequences extracted by pseudo-position specific scoring matrix (PsePSSM), detrended cross-correlation analysis coefficient (DCCA coefficient), and an FP2 format molecular fingerprint descriptor of drug compounds. In addition, the synthetic minority oversampling technique (SMOTE) is employed for dealing with the imbalanced data after Lasso dimensionality reduction. Then, the processed feature vectors are put into a random forest classifier to perform DTIs predictions on four gold standard datasets, including nuclear receptors (NR), G-protein-coupled receptors (GPCR), ion channels (IC), and enzymes (E). Furthermore, we explore new targets for breast cancer treatment using its risk genes identified from large-scale genome-wide genetic studies using PsePDC-DTIs. Through five-fold cross-validation, the average values of accuracy in NR, GPCR, IC, and E datasets are 95.28%, 96.19%, 96.74%, and 98.22%, respectively. The PsePDC-DTIs model provides us with 10 potential DTIs for breast cancer treatment, among which erlotinib (DB00530) and FGFR2 (hsa2263), caffeine (DB00201) and KCNN4 (hsa3783), as well as afatinib (DB08916) and FGFR2 (hsa2263) are found with direct or inferred evidence. The PsePDC-DTIs model has achieved good prediction results, establishing the validity and superiority of the proposed method.

23 September 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
ZRZhiwei Rong
Zhiwei Rong
JSjiali song
jiali song
YYYipei Yu
Yipei Yu
LMLan Mi
Lan Mi
MQMantang Qiu
Mantang Qiu
YHYan Hou
Yan Hou
The integration of data from multiple modalities generated by single-cell omics technologies is crucial for accurately identifying cell states. One challenge in comprehending multi-omics data resides in mosaic integration, in which different data modalities are profiled in different subsets of cells, as it requires simultaneous batch effect removal and modality alignment. Here, we develop Multi-omics Mosaic Auto-scaling Attention Variational Inference (mmAAVI), a scalable deep generative model for single-cell mosaic integration. Leveraging auto-scaling self-attention mechanisms, mmAAVI can map arbitrary combinations of omics to the common embedding space. If existing well-annotated cell states, the model can perform semisupervised learning to utilize existing these annotations. We validated the performance of mmAAVI and five other commonly used methods on four benchmark datasets, which vary in cell numbers, omics types, and missing patterns. mmAAVI consistently demonstrated its superiority. We also validated mmAAVI's ability for cell state knowledge transfer, achieving balanced accuracies of 0.82 and 0.97 with less 1% labeled cells between batches with completely different omics. The full package is available at https://github.com/luyiyun/mmAAVI.

28 April 2023 in Tumor Discovery
Verified
Journal Article
Open access
PDF file
JSjiali song
jiali song
ZRZhiwei Rong
Zhiwei Rong
XZXinwen Zhong
Xinwen Zhong
YLYuhong Lu
Yuhong Lu
JHJike Huang
Jike Huang
YHYan Hou
Yan Hou
There is considerable interest in expediting late-stage therapy development by efficiently conducting trial designs that encompass multiple therapies or multiple subpopulations simultaneously within a unified protocol. Such trial designs are referred to as master protocols, with specific designs characterized by the terms umbrella, basket, or platform. These designs, in contrast to the traditional trial designs, are full of complexity. What factors should be considered in designing a trial ensuring the safety of human subjects and demonstrating the efficacy of new therapy? This paper overviews the master protocol framework, comprehensively unifies the definitions, and illustrates essential design elements of representative example trials conducted in drugs and medical devices. Besides, to understand the master protocols deeply, it is also a need to summarize the commonly-used types of master protocols in various disease and treatment fields, along with the reasons for these phenomena by analyzing the characteristics of the diseases, the mechanism of therapeutic products, and the principles of various types of master protocols. Finally, we also propose practical considerations, including the design, ethical, statistics, and funding considerations that arise from implementing complex master protocols. This information serves to guide practitioners in designing more effective trials and identifying potentially valuable therapies.